Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 101856872 | 10185687 | 2 | F | 2013 | 20160802 | 20140521 | 20160810 | EXP | US-ASTRAZENECA-2014SE33440 | ASTRAZENECA | 72.00 | YR | M | Y | 72.60000 | KG | 20160810 | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 101856872 | 10185687 | 1 | PS | SYMBICORT | BUDESONIDEFORMOTEROL FUMARATE DIHYDRATE | 1 | Respiratory (inhalation) | 160/4.5 MCG, 2 PUFFS BID | U | U | 21929 | ||||||||
| 101856872 | 10185687 | 2 | SS | SYMBICORT | BUDESONIDEFORMOTEROL FUMARATE DIHYDRATE | 1 | Respiratory (inhalation) | 160/4.5 MCG, 2 PUFFS BID | U | U | 21929 | ||||||||
| 101856872 | 10185687 | 3 | SS | OMEPRAZOLE. | OMEPRAZOLE | 1 | Oral | TWO TIMES A DAY | U | 0 | |||||||||
| 101856872 | 10185687 | 4 | SS | OMEPRAZOLE. | OMEPRAZOLE | 1 | Oral | TWO TIMES A DAY | U | 0 | |||||||||
| 101856872 | 10185687 | 5 | SS | PANTOPRAZOLE | PANTOPRAZOLE SODIUM | 1 | Oral | Y | 0 | 40 | MG | QD | |||||||
| 101856872 | 10185687 | 6 | C | SPIRIVA | TIOTROPIUM BROMIDE MONOHYDRATE | 1 | Respiratory (inhalation) | 1 PUFF DAILY | 0 | ||||||||||
| 101856872 | 10185687 | 7 | C | SPIRIVA | TIOTROPIUM BROMIDE MONOHYDRATE | 1 | Respiratory (inhalation) | 1 PUFF DAILY | 0 | ||||||||||
| 101856872 | 10185687 | 8 | C | GABAPENTIN. | GABAPENTIN | 1 | Oral | 0 | 300 | MG | QD | ||||||||
| 101856872 | 10185687 | 9 | C | TYLENOL EXTRA STRENGTH | ACETAMINOPHEN | 1 | Oral | 2.0DF AS REQUIRED | 0 | 2 | DF | TABLET |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 101856872 | 10185687 | 1 | Asthma |
| 101856872 | 10185687 | 2 | Chronic obstructive pulmonary disease |
| 101856872 | 10185687 | 3 | Gastrooesophageal reflux disease |
| 101856872 | 10185687 | 4 | Gastrooesophageal reflux disease |
| 101856872 | 10185687 | 5 | Gastrooesophageal reflux disease |
| 101856872 | 10185687 | 6 | Asthma |
| 101856872 | 10185687 | 7 | Chronic obstructive pulmonary disease |
| 101856872 | 10185687 | 8 | Neuropathy peripheral |
| 101856872 | 10185687 | 9 | Pain in extremity |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 101856872 | 10185687 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 101856872 | 10185687 | Arthralgia | |
| 101856872 | 10185687 | Candida infection | |
| 101856872 | 10185687 | Eye pain | |
| 101856872 | 10185687 | Gastrooesophageal reflux disease | |
| 101856872 | 10185687 | Headache | |
| 101856872 | 10185687 | Pain | |
| 101856872 | 10185687 | Pain in extremity | |
| 101856872 | 10185687 | Respiratory moniliasis | |
| 101856872 | 10185687 | Vision blurred |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 101856872 | 10185687 | 1 | 2012 | 20140407 | 0 | |
| 101856872 | 10185687 | 2 | 2012 | 20140407 | 0 | |
| 101856872 | 10185687 | 8 | 2011 | 0 |